$62.02
0.76% yesterday
Nasdaq, Oct 13, 10:17 pm CET
ISIN
NL0010696654
Symbol
QURE

uniQure N.V. Stock price

$62.02
+47.19 318.07% 1M
+52.85 576.34% 6M
+44.36 251.19% YTD
+56.38 999.65% 1Y
+42.79 222.52% 3Y
+25.60 70.29% 5Y
+42.94 225.05% 10Y
+47.41 324.50% 20Y
Nasdaq, Closing price Mon, Oct 13 2025
+0.47 0.76%
ISIN
NL0010696654
Symbol
QURE
Industry

Key metrics

Basic
Market capitalization
$3.8b
Enterprise Value
$4.0b
Net debt
$130.1m
Cash
$377.0m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
266.4 | 209.0
EV/Sales
275.5 | 216.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1.2%
Return on Equity
3,547.9%
ROCE
-30.6%
ROIC
-84.6%
Debt/Equity
-126.8
Financials (TTM | estimate)
Revenue
$14.3m | $18.3m
EBITDA
$-150.8m | $-155.0m
EBIT
$-166.3m | $-182.5m
Net Income
$-199.0m | $-189.9m
Free Cash Flow
$-174.2m
Growth (TTM | estimate)
Revenue
-48.3% | -32.6%
EBITDA
34.1% | 5.8%
EBIT
30.9% | -3.0%
Net Income
30.1% | 20.7%
Free Cash Flow
-57.5%
Margin (TTM | estimate)
Gross
82.6%
EBITDA
-1,051.8% | -847.7%
EBIT
-1,159.9%
Net
-1,388.0% | -1,038.8%
Free Cash Flow
-1,215.3%
More
EPS
$-3.6
FCF per Share
$-3.2
Short interest
18.1%
Employees
209
Rev per Employee
$130.0k
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a uniQure N.V. forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a uniQure N.V. forecast:

Buy
90%
Hold
10%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14 14
48% 48%
100%
- Direct Costs 2.49 2.49
91% 91%
17%
12 12
903% 903%
83%
- Selling and Administrative Expenses 46 46
29% 29%
324%
- Research and Development Expense 135 135
22% 22%
940%
-151 -151
34% 34%
-1,052%
- Depreciation and Amortization 16 16
28% 28%
108%
EBIT (Operating Income) EBIT -166 -166
31% 31%
-1,160%
Net Profit -199 -199
30% 30%
-1,388%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Positive
Seeking Alpha
6 days ago
uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent efficacy and prior alignment with the FDA on accelerated approval position AMT-130 for commercialization in the near term. Relatively modest volumes are needed to justify uniQure's current valuation, mea...
Positive
MarketBeat
10 days ago
In one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130.
Neutral
GlobeNewsWire
15 days ago
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary s...
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 209
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today